-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CfDRwbWqFq2nwkoo+Xe9y8rhjCiEkYPD1HIjDYmJzCsf4jiPLVyrVOZGTdN6r4uI
 c8xXrHNmhvGr+8TXlGYN2w==

<SEC-DOCUMENT>0001019687-10-003768.txt : 20101022
<SEC-HEADER>0001019687-10-003768.hdr.sgml : 20101022
<ACCEPTANCE-DATETIME>20101022170000
ACCESSION NUMBER:		0001019687-10-003768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101018
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101022
DATE AS OF CHANGE:		20101022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		101137778

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-101910.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<html>
<head>
    <title>aethlon_8k-101910.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C. 20549</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CURRENT REPORT</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Report (Date of earliest event reported): October 18, 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AETHLON MEDICAL, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or other jurisdiction</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of incorporation)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">000-21846</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission File Number)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13-3632859</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS Employer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="29%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8910 University Center Lane, Suite 660</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">San Diego, California</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">92122</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s telephone number, including area code: (858) 459-7800</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former name or former address, if changed since last report.)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: white" align="left" noshade size="1" width="100%">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ITEM 5.02</font></div>
</td>
<td align="left" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Election of Director</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Effective October 18, 2010, Mr. Rod Kenley was elected to the Board of Directors of Aethlon Medical, Inc. (the &#8220;Company&#8221;).&#160;&#160;Mr. Kenley, age&#160;60, was elected by a unanimous vote of the Board of Directors of the Company, filling a vacancy.&#160;&#160;Mr. Kenley's election brings the number of Directors to five. He will serve until his resignation or removal, or until his successor is duly elected.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and Vice President of Electronic Drug Infusion. During this tenure at Travenol he helped to develop and manage the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.&#160;&#160;In 1991, Mr. Kenley founded Aksys Ltd. to develop and commercialize a daily home
 hemodialysis system which was launched in 2002 as the PHD system. In 2004, Mr. Kenley initiated the development of a second generation home hemodialysis system in partnership with DEKA Research &amp; Development Corporation in Manchester, New Hampshire. In 2007, the assets of Aksys Ltd. were acquired by DEKA where Mr. Kenley is now employed and continues work on the second generation home hemodialysis system along with several other new dialysis products.&#160;&#160;Mr. Kenley is the author of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at the Kellogg School of Management and other business schools in the area of entrepreneurship.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with his election to the Board of Directors, he will be entitled to receive compensation, including equity compensation, under the Company's Board of Director compensation policies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On October19, 2010, the Company issued a press release announcing the election of Mr. Kenley to the Company's Board of Directors. The full text of the press release is set forth in Exhibit 99 attached hereto.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ITEM 9.01</font></div>
</td>
<td align="left" colspan="2" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FINANCIAL STATEMENTS AND EXHIBITS.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(d) EXHIBITS</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release dated&#160;October 19, 2010</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;AETHLON MEDICAL, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;<font style="TEXT-DECORATION: underline"><font style="DISPLAY: inline">/s/ James A. Joyce</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A. Joyce</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dated: October 22, 2010</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release dated&#160;October 19, 2010</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div><br>
&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">4</div>

<div style="TEXT-ALIGN: left">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>aethlon_8k-ex9901.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div>Exhibit 99.1</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><img src="logo.jpg" alt=""><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aethlon Medical Announces Appointment of Rod Kenley To Its Board of Directors</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">San Diego, CA. &#8211; October 19, 2010 &#8211; Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that Rod Kenley has been appointed to the Aethlon Medical board of directors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and VP of Electronic Drug Infusion.&#160;&#160;During this tenure he conceived of and managed the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley founded Aksys Ltd. in January 1991 to develop and commercialize his concept of a daily home hemodialysis system which was commercially launched in 2002 as the PHD system.&#160;&#160;In 2004, Mr. Kenley initiated the development of a second generation home hemodialysis system in partnership with DEKA Research &amp; Development Corporation in Manchester New Hampshire.&#160;&#160;In 2007, the assets of Aksys Ltd. were acquired by DEKA where Mr. Kenley is now employed and continues work on the second generation home HD system along with several other new dialysis products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at Kellogg and other business schools in the area of entrepreneurship.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;I am honored and excited to be asked to join the Board of Aethlon Medical.&#160;&#160;In my 30+ years of experience in the area of blood purification therapies, I have rarely seen an extracorporeal device that has the breadth of market opportunities that are engendered by the Aethlon Hemopurifier&#174;. Firstly, it represents the most logical solution as a countermeasure to a bioterror attack owing to its expected efficacy regardless of any genetic manipulations that may have been engineered into a bioweapon to render vaccines impotent.&#160;&#160;Furthermore, it has a long shelf life and can be ready to deploy at a moment&#8217;s notice.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Secondly, it promises to be a highly contributing adjunct to drug therapy for a variety of chronic viral diseases such as hepatitis C and HIV that may well significantly increase the percentage of patients achieving a non-detectable viral load status.&#160;&#160;Thirdly, it has the potential to be a front-line therapy against pandemic viral outbreaks particularly in cases where vaccines do not exist or are ineffective.</font></div>

<div><br>
</div>

<div>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lastly, the Hemopurifier&#8217;s ability to adsorb exosomes, the small particles that are released by solid tumors to provide localized immunity by inactivating the host&#8217;s cellular immune defenses represents a major opportunity in the cancer arena.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consequently, I look forward with great anticipation to working with the Aethlon Board and its employees to capitalize on this wealth of opportunities in the coming years,&#8221; stated Kenley.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from the Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg Graduate School of Management, also at Northwestern University.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Rod has been instrumental in the commercialization of some of the most important advances in the dialysis industry,&#8221; stated Aethlon Chairman and CEO, Jim Joyce.&#160;&#160;&#8220;His presence on our team is already impacting our endeavors and we believe Rod&#8217;s unique insights will benefit our organization in the years to come.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Aethlon Medical</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Hemopurifier&#174; is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier&#174; captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier&#174; can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human studies have documented the ability of our Hemopurifier&#174; to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.&#160;&#160;However, our initial clinical and commercialization focus is to establish our Hemopurifier&#174; as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier&#174; in India as we advance our clinical strategies in the United States and the European Union.&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">In vitro</font> studies conducted by government and non-government research institutes have also verified that our Hemopurifier&#174; has broad-spectrum capabilities ag
ainst bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.</font></div>

<div><br>
</div>

<div>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a therapeutic device, the Hemopurifier&#174; provides us with a pipeline into four significant market opportunities:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Cancer</font>: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Hepatitis-C Virus (HCV):</font> As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Human Immunodeficiency Virus (HIV):</font>&#160;&#160;Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Bioterror and Pandemic Threats:</font>&#160;&#160;Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Hemopurifier&#174; is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier&#174; is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In design, our Hemopurifier&#174; is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier&#174; via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier&#1
74; in as little as 15 minutes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contacts:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">James A. Joyce</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman, CEO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">858.459.7800 x301</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jj@aethlonmedical.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John P. Salvador</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director, Communications &amp; Investor Relations</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">858.459.7800 x307</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jps@aethlonmedical.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jon Cunningham</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RedChip Companies, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">800.733.2447 x107</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jon@redchip.com</font></font></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><br>
4</div>

<div style="TEXT-ALIGN: left">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`![`4D#`2(``A$!`Q$!_\0`
M'P```0('`0$```````````````D*`0(#!`<("P8%_\0`4Q````8!`P,!!00&
M`PD,"P```0(#!`4&!P`($0D2(3$*$Q1!414B87$6(S*!D:$7&-$9*#@Y4G*Q
MP?`:)$)7=7=XMK>XX?$F,S='4UAB=GF"E/_$`!T!``$$`P$!````````````
M```!!@<(`@4)`P3_Q``\$0`"`@$#`P($`P4&!04````!`@,$!0`&$0<2(1,Q
M%")!40AA<14C,I'P%R1"@:'!%E)RL>$8,V/1\?_:``P#`0`"$0,1`#\`?\:-
M&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1H
MT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-4A4'Y"7QZ_M!Q_(1_E\PXU
MY2[7JK8YJ\[>+W9JW3:76H]62G[3:YEI7X&&:)&`HN9*5D%$FC5N<YB(%.HH
M4WOSHII$<*+$3!8UDE:)(XIGEF=8XH$C9YGD=@B(L:@L7=F"JHY+,>!YUBSJ
MBL[D)&H+-*Y"1*H')9I&(55`]R2`/KKUBI@(F8PCV\!Z^G'D`_\`#Y_D/IJW
M*NF80*43&,(]H^[2.H`"(%'[YB@8J?@Q1$1$`#GR(<#PV2W=^T7TFOO9"F;+
M,;-,M+(BH@?->333=:QRW<)AW(KU6BI,V-TNZ9S]JC9_(O:1%@"9'B"LJS51
M,JWUSKU"]\6Y)P\'*^YG):D&[+[I.BX\EU,24!HU]ZDN1D:N8Y&O&GT&ZR?>
MW<W20M$L0AC('DU$.$PL]L/\(W57>T%3)Y"O1V?A[*K)!/GPW[19&\B>/%PB
M2TL9'CML+6?N!\'_``PON;KMLK!2V*E%Y]PWZS%'CQI[:@E!\Q&])Q7+#W+Q
MB9.&!!/G70DR!FG#6*D5GN3LMXNQNS13457>W_(%2I[9%%NF91959:PS$:FF
M1)--1110QP*F0AS'$I2F$,%$ZANP$ZA$R;Z]FQSJF*FFF3<SA`3'.;P4A"!=
MQ,<YA\%*4!$>>`#7-X/#QJKM6068M%I!P<ZKJ1<(%=OW:YP$#+N73SX@ZBQ@
M'@R@`4X^HF$WWM78M41`2B1/@>0$"HMR"(?Y/<5$#`'R'M$!$/00#QJP5+\!
MF%$"-D>HV8>XJ\R/2PE58'DY^;T(K-YRL8Y^7UG5F4=Q1&/IK&$_XELJ[%H=
MHT^S_"LN<O+(J\CA7].KZ995)[O3)3N!"DC@GJ#T[*&-<BLR2&/<D42^,%`*
M<CVF6^L6=F<IB]Y#$<PD@^2.4Y.3D$IQ[B?>#QYU[PJ@``"8!*!@``*<@D$P
MF_9#L,!3=P_Y(@`\!Z#Y`.5JTC&,?(I3$:V+%S#<Q#-IB+.>-EVPD)V#[B59
M^ZD4>\!'N%NZ;B/S$?(ZW^P)U/=^FW!U'IT;<?=[95VAT4E*!F=W_2]3EH]'
MP1@DI<E'US@FI`,(#^B%KAG)P-P*;CM*GIE[G_`CN*G!-<VEOK$Y>:,%H\7F
ML0V+MRA57Q%?J-<JL_@\B40J"4"OX<ZWN%_$=CGD6/.;?GIQR$=]G'7YLAZ7
M!\]\%J.N_LW*O!+(25/>@^4ZZ*:!TSE,*9B&`#"413'N+R`!R'/(^0]#!SX,
M`@/GG5;3<K9][0OA')+F)I&[2H$VZW:2=MF"&0H5]*6W"$L]<]J1%9%\Z:-[
MACDB[P?<F"<BYNJPK4Z#Z6O#9O\`$E:N$X>Q1\]&0\U#2,5.0LZR;R<3-P3Q
M&5AY2.=HD7;/HV19JK-'K)PBJDNU=MUU4G22@&2Y(`*'J%O/8.\>GV07&[PP
M5[$6)>XUIIHB]&ZB\\24LA$9*5A6`'B.<NC$)(J/\NIZVWNO;^[:?QFW\G!D
M%3@35@_;?K$\`BU4E"6(@O)(=XPKJI:,N."?1:-4"JB81`!)\^.0,`\A]>?E
MZ\<>O'C54HB)0$W'(^O'/'K\N?.F:K<^""C>?E<!6X'CN"\\E>?'(\<Z<9!'
MN"/U\'^7OJ;1HT:RTFC1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&
MC1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&I3'*7CN,`=P
MB`<_,0#D>/W>=2^]3'C@X")N>T`$>3<>O'[_`!^>A0`$`$0YX$?7Y<E$HC^'
M@?76(\R9CQ]@#&UZS#E2>:U;'>-ZTK9+'..52A[ELF<4&S%FW4]V#V7F'IF\
M3"1[=8SN4EWC*.01%=VV!7*"*Q;M04ZE>:U:M3Q5*M6",R3VK=AE6"&NB\M(
MSLP4*H+%N0`3P#YS315XIK%B1(*U:"2>Q/*ZHD2)Y+LS$!8U4,SL?`"D\@:Q
M1O#WB87V6X;E<OY@GE&K8B;IM4*A"@B\N61+$1H9=K6:=%G70*[?NQ,B1Q(O
M%FT+#%72>S#UL@)/>,0=\6__`'#;^;FK+9<E#5_&L3*JN<?X%JLHY#'U5:M'
M"YHB2FQ=*D0NV0@;*)&D+[.@!&$DFX+2Z]!1YVP'\OO3WE9+WV9RF,W9'*YB
M(@A"1&)\<$=_'0F+:*1`J[&#:N&R!6TA:9T#KS]SL<@"<D_E5SL6!(VO-8R$
M8ZI!R'\O/GU]!]?R_#QKK3^';\.&'Z;XJIN3=N.KY#J%>#2]]@Q7*>WU9!W0
MT86,T+V"I*2V9'GX/<M9UB\R45ZJ=5K^\;]G#XF>6EM:(($2!Y8)\F4*L9+4
MBL"(PX!CBC"`*!ZA=M`B(\`)^\OW1*`%$B?("=0!*D8H"0"F44,4HD*9,QS!
MP4PFXFT:-6UYD)+2RO*YXY9^`````J*H"H@XY"J``23]=0U&@C01KP$7PBA5
M!4$\D,P'=(223WN6;SQSP!HT:-&C6>@?0?GJ7CGCT_@(#Z_(>?'I_MSJ;1K%
MU+#@,4;D$.O'<..>0.>5X;QS\O/@>=&J)B$.04CD3.F)#$,F8I1()#\^\)VF
MY+V&X`QRB'!^"]P#P&E(M@'4ZSGL$GVL/%.9#)>W>2>.%+=@V5DG"P0Z;IVU
M=N[3A]XY=BWIEU5*G()K1"KK]!K,J[3&5@X&1`UCTG'H`QB"!B&,10O(I'*(
M_<5`IA2.8OHH0BG:91$_*:Z8&15`4U#!IJ;PVO@-[X.[MK=6/@RN'N,S35YX
MRR1NT?IFU"D?!CNQJ2T%N+MLQ/VF-@0-;/"9C)[>R,65Q%J6I>C="LD+-$)4
M5E8P6%0JL\4O'9()`Q9"5YXX&NF1MSW"XEW.XGKF:<,V]*UTBS)*E276!=K+
MP,LR4.26K5IBGIOCH&QPKE06LE%O0*=,I$'+<SE@X:/G.>FZA%4BJ)G*<H]P
M`8H@(<E.8I@'CC@Q3%$IBB`&(8!*8`,`AKG?]-G?W<.G]FY"QI_:DS@3(#^+
MCL[XXB"%<+/F#=(T9'9!JC%0JJA+K1VJJ(-F[95JE8ZTS/79MZD0K&8BN@U3
M+;6KK4*K<J7,1]EIUOK\/9JM8X9P5[$3D!.LFTE$RL:Z1]X5RQD8]XW>LERF
M,"K=03J'*)3"/'SKKT1RW1?=4M!_5M[8RTCV=M9)I%L=D"@?$8>W8CCCA?(X
MYF19WA5(+"NLL*(`\<=\NF/4?'=0<()T'H9:C^XR-1@5;O3A6L0JSN[5I&*A
M68EE?E&)^5Y/6:-&C4'ZDO1HT:AS^`C_``_UB&C1J.C4.>/4!_E_J'YZ.1^@
M_P`O[=&D)`]R/Z_K_O\`8ZCHU3%3]K[ION\<>G)N0`>0\^@<\?G^'G4H+!XY
M*8HB(@'/;Y$.?3[W/H'/IK'O7N[/);CGA59OM[E00/?SR?'UTOV_/CC[>?;S
M[#W^NJVC5`JX"(@)#%X^HE'GR(>`*81^0^H:G]X/_P`-3^`#^_P8?[?PUGQ[
M^QX')X((\_F#QS]Q[CQR!R-8EU4\%AS^7S<>WN5Y`]_8\?Z'531K#6?-PF&-
MKF);AG;<%D&"Q5B&@(PB]POEG4<$A8(EDL<748('?P*#UZ925LTW$0K%)!HL
MHX?R+5!,IC''MQ-LWWW[6M_U#N^4MI63$\MXYH&4Y3#<W<F=<M-;B'-ZA*A2
M[M+,H4MOAH"0EXYE#7VOE^V6C$T8\>'=)1SEXDW!=3$'D<CV/W!'^AX.LM;>
M&.0@`)S%(`B``)C`4!$1```!$0\B(@`!ZB(@`>=!3D,/!3E,(`4P@4P"(%,)
M@*/@?0PE,!1]!$I@#T'6%]QMIL-&P-FN[5-Z2*M%.PYE.TUR7,W:O314_7Z/
M-2\,_+'R#9W&R`-9)FV<'9R3==DN"0)N&ZZ1C)&96^S"=9/J2=1/?QEC"V\;
M<@.8L9U?:!D#*L#6#8<P'C\K&]PF9L`T^+G?MK%V+J78G(M8&[VN/^S7,JK$
MK%D2NW#%9XV9*LUT:?>:-0$>/QY_\_G^6CGCY#_+^W1I"0/<C4=0$Q0XY$`Y
M\!R(!R(`(B`<^O@!'\@$=1TU8]J<ZC^]#IQX2VG7#9CF8,,V3)F5;]6KM)!C
MC%.1#SD+!T^.E(AB+;*M*NT?&D:R#I=85HMDT=K"MPJY.DD""AI=.I0,4PF`
MIBB)!`IP`0$2&$I3@4P`/)1$ABF`!X$2F*;T$!&;21?0KW+YUWD=*W:9N5W*
MWH,C9JR9'9<=7:X)UBH4\DR:LYZR=2:Z8*_1("K5B-,QJ]:A6"Q(N$:(NUD5
MW;DBSI<ZXJZ:-'^VC1J'/KX$>/R_/YC^.CGSQP(?P_#Z"/UT:3D<\<CG4=&C
M1HTNC1HT:-&C1HT:-&K1V80(4"J`0QO>`'S$>$CCR!>TW<)>.X`\>G(\AR`L
M_/:%MY+V[9-JFR2CS!U:AC-&#R+G`6#E<J,]DZ13.YH-&>%2%`JR%'@%FMZD
MFZRBT>I.VNEN3IC)5@XLW:>3[U`XNQY>,G6I<6U7QO3K5?K*Y`Q"?#U^GU^2
MGYI<15421_51K!R<`6522[BE,HJF4O<',9O^0[+F#(F2,O7);XBW99R%=,CV
M,X`8I4)6Y6.1G7$:W2,JX*A'0Q7J</$-$5ET6,.P8,FZ@I-R:N5^"_IY6W'O
MS([YR,*34-@01VJ$<T2RJ^YLC')!CYE$@*^EBJD<V3G"=K0LD<RGO(U7S\0^
MZYL3MBEMRE(T5K<ML0SRABOIT(61K#,RD,(F)C5T^;O7U`P[3PWEA*43"<P%
M$XB(B<2E$PB(=HF[A*!A,)/N=XCW]GW.0+XU:O72#!LNY5.!"))*K'$4P5*F
M1%1JF4!3[DQ.9RL\30((*`"9^WN#M,`&N>X`X``'R(``!]X>/'<;@.!,!"]Q
MS]H#P0AS#P!1$%B.B;LK+NOW0%RC<X9.2PGME=U^Y3K&1245C+AE9\E).,:U
M$A4Q52>-(==LK=[8FW!TB9C&0$+,-7,;:4R&Z0[]WIA^GNT<WN[,/Q5PU>1E
M@C[1/?R'*QU,9!W*1ZUNR\<08_*O)9CP#JI.WL%=W+G,7@L?V?$7)H#(S#N$
M./+*UF?D=W8J0@N67Y@%Y`)XU[7"70%WJY>QU7LAV"U8EPN>TM6TI%46_N[/
M)W-A"O&J;N/>V%&M5MQ'0\E))+`9:M*.W$A#E3(5ZY3?"Y8M\N_[FYW:_P#S
M!;=?_P"')?\`+_T=\\?/CT^>GD1`.H8%A$A@.8ID^#=P%(8G/W3%Y(;U#@2B
M8!`>X!$.-7?:;Z_EY'Q]?E\_]N=<M9?QC]<);%B:',8>&&:9I(H1MO!S101O
MV]D$4EJH\I$2<(Y8\F0.QY\DW3@Z"]/*\,4$M&[<FBC19;$F2MQM)(54EBD<
M\:*"?957P/')X[M,S3>S=;N`,/\`?![=>/E_O')OIQ^%<$/Y^?74@^S>[M"<
M"IN'VZ$`1^[RTR03N,4ICB7O6K8E`.PIC&X34$"D$>T0Y$KS(R0>3#QX`1]1
M$>`_``\C^0>=::;]-XV+]ANT;-.[+*[M)"M8BJ[V5C8)4R'VA=KVX-]EX^Q]
M#D$QS#,W2WO(6(;*)G2")0=.)667C&,:_=L_+_U@]>2>#N/#1JQ[2R;5P)=0
MW`!`%$J".>2>"%`/'D'7O_85TV\$XBV."K<KD[Q;Y2K<<?$\'GR"".&'(/OI
MB'O*V,;A-B=W@ZEG**@743<47[FAY$I$@XF:)<$F*Z)'[!JYD&T3+Q5@9(N6
MRKN$DXY!\W;JEDHO[5;&*GK44/0/]?K^_2CO37ZOF2>M^PSKTP^H3(XZCLT9
MH-8<Q;%,M5^D-*#'5'+%,">O/]%<LWA#OQ^QH>N>_0HEC=0SVUS='CLC0%WM
MEZML]`BY3OEH6Q5>9G:K<8-]6+A4IV5JMMK<JG\/(P5G@GKJ,FHAPGY(HJPD
M&3QJ<[<ZJ8F1Y`W:=,QKW?AKZX2]7=MWJ^X363>NW[:09)ZZK6ARF-M1L^.O
MP48PL,+(]>[%;:)1\XA:41B2)-5AZK]/$V!FZXHR32X/.-)-CGL,7>O<+(EC
M&F4\>(AZ$D((5"LI[.2'.K+1J`#SS^''\P`?P_V#4=641E/;+&1R&#)(OA@R
MMX96'!!##D$'W'(U%@//M]"1_FI(/\B#_MJ0R9#E,4Y"G*<@IG`Q0$#)F,0X
MD,''`E$Z:9^./VTTSA]],A@=<^SP;RG,]!7?8[>YERO)4)L]RK@ET^<]Y38\
M=2$6RO6.FHK=W"E0M#QO;XIB4YW*L%=7X-B)1,`H#=J3K/>T[/C[:QN>P9N$
M;J*IQ^-<@0;VWECB'^/?XWF9`8#)<65'WR*+]5Y0)>>,R2<+(IA*LHH#?J_>
M*IPSUXZ<U>HW3'.8&*NG[4HUSD]ME(T'H96BLLD4,?CB);<3V*C=O"_WEN5)
M.GOT[W5-L[=F*RR2%:DMF*ADHNXA)JEZ6.!O40?+)Z,ACG0,/#Q*001R.F0F
M;DQ@[Q,/[7'`?=`1\`/'D!'U#GQQ\^>=5=6#55-54QT0*=$Z29T7)#)J)N45
M")JD42434/WI`"O!#*%()O)D^\GWS7^N(J%RH[QPXY5_'`[T)1R!]`64GCZ?
M4`\ZZ,`KQ\O=V^."Q)YY`;D,>>5//RGVX]O&J:IA*!1`P%^\`"(EY`0'D..>
M0[1$>``P\_>X#@>=-O.K%[27M]Z7.;GNUL^WO-&X7<4%+IUTC(&N/*O1,9."
MWA9PG!5U[?7J]LMQ9I9JU.^5&`Q/8V7>]C8]!TJ\._1C7(2P'$G!"@8W<40Y
M\@`@("4YOOICVD.!3'`HB82`8"E,80#6"HO;I@*NYFLFXEAA+%S'/]QC&L19
M<Y-:)6W&6I>O1</7:\Q@)#(SN+6N`5R/BH"(31@$IE&#[X[XW[.-(.%U5LM+
MII"T]INZIF289K;\+^ST;I)RE=KI)S86?]8K)D*Y=,C@9T+6Q53:97(EL5FB
M(%=-U`>*(G$%5%DR_JM5\$>V:8,DLMK8NWL[)LP;-6R+R)BGUNC;HYS<>H/)
M%,ZCN3R1CM[BG#N0H&!C6RT;(E+48J^V1^T>'^%KIS)-@D'I(+&.D!@24*H(
M)=R?:(=HJ=G(`H/80Y4^X?>&3,(@4IA*!C`!1YK_`+8-NYV*[BLL;7:#MWM6
M-<O[B<.MLHQ.<<J8ODX^=:P%.ER4E2BXFL-YA(9Q$Y&D&L\6W3B,2SN+]?#[
MTEKBW42TF,@R_P`*:QX'MQS^?'^7N?;\@#X`UT=:5<:QD6CU'(%'LD3<*9?*
MM7[G3[?77:4C`6JKVB':3E?L4$^:F,@_AIN*>M)..=MU!2=LW2*R)A(<@Z2%
MWS=:O:[LZM<QBB'AK'G[-]<53;3M%H;UI%URGS3IHDNQ@K[D=ZC(1$),.P<M
M@&#A8NT6!J9RFFYB$ESIHJ)U;%-UMNVP>R[;;LVPTDNODXF'YK%.+GSU?XAQ
M'V:V[@+UC"GR"`K.&RBB>/JZY"?CV8.3(H1E9,B5J=NV]T-E[/KM#QE+1%]W
MIY:^P[9?&60'5#PXXOCQA)O:RXAH^.G;_E`AY9,3/;M;I^RFCD;44I9$D5#K
MNF2S->?>*:G?IET_VY_P-N7JQO\`IY?);5PV9I[>V]MG"W)L5/NG/V:Z6YH[
M66K!K="A5A)FLM6B>6=>Y(IXWBDBEBW>.[\RNY<1L3:E^'%Y>_0GRF3R\T$5
MM</1B953TZMA?0LV+)#QQK,PCC!7]VW>KQ9H4ZX^]EK737U_T<LVIX]5C498
M+.6WYQ:PZ,8=,JQ9$;.KL\-"N62B9B"19U]CI=P]H**%X/I1#8EU;=L&_)\%
M+IKJ8QAF9)BM**8GR$:)-)3L:U%4KZ2Q_9(B5<5RZM&)4E';UDQ<M[5&,$%G
MLO4H]H`KE4J3M5=``]]:($I@-R!1GHP3=O(<=W:L!?3P)0$X>0`5%!Y,+)7K
M88VA=H^_''>X;;<I%4V5N=8@\^MTJ?\`!MX2NYFQS=F[6<G(UM#BG'LH^[H)
MPC^S1HM%C3#Y[>'ZBB[VT/2ING8^WNFW6?(W]GX_IQ)TMW)+B[V0VUE\1F=T
MY?%6K&+B$LM#-T,[/EI.ZU#^]CO4[E!QZ5DR02\IZ>@W/GMT=.:U'<%C>$6[
M,'^T*=',8Z_1QF/M0"_*L?[0I7,=&&,<+_*]2:"51S'VN"9&UC'VGKKE51S`
M;Y>C&7;O/C:"O-MS,,_CDF'5@#&83>!MT:ICX]2J7QQ.6B9J4")K<)BN^998
M4Q35BM).=#OVC&C](C:?D7;=9]J]JS<_O&X>VYX0M4#EB$H;2.:6;&F*:&G7
M%8>1I=@77<-G&,EI,7J;PB:S6:0;D9`=H"KQX#[1Y-PV0?9\]V&46L-'LG.0
M*ALWNX'*Q23D$?TEW-;:WJ1'+A1$CTZZ#%V1@!W!@6*T3(V$"IE[-:<>Q;14
M6_Z6N>%'\;'O3EW_`.4B%.[9-G)RD+MTVLF*0IEDCF*4#'.8``0`!.80_:-S
M6*2*2"22&8`2PNT4@#=W#QL59>>U>2""#X'D>.?<S=&Z2QQS1N)(Y4CD1U'A
MED"L#YX]^1S]CS[\#2A.R'JU5KK`=.'?+G.MX7F,'(8RKN<,3.*Q-WR*OSJ3
M52P`WN/VZG(1=<K)6357])S1J+55FY$YXU5R5Z855&K1F+[(;F#&&`]_6['-
M&8[K!XXQ?C+IL9FM5ZNUE<BWAX"$C-Q6UI=P]6]V15RZ64[T&<=%,$'<M,RB
MS6*B63V2?,VB_2KW5Q\?&[6-S*<<Q9L$W.!,UNG!&35!J5=S_1C/M_B%BH)I
M@JO[A%%$53@904D4DQ-V)D`O',Z2NT"Y=0'?#A_9;7KM;:'1]P#E>'SW+U&6
M>1KA7`^/GL=FF\L7Z8).X*46^+Q?"2-+C[;#S=8;9098_F7<6[?Q3%5KAKUT
M]`W*^VNX.J%]E*AM+V:77<+56J:[",RGD/*),)(S<R@84PD(+&#'&^3K.\K#
MDO#A@I8IZEV)=(WNGD#&K$/VX@Q3[<+#+ST''9TZ?$C%U9T^7-8[?B'<(VL5
M@AXOX54[4D1CBZXHJT=8)+XY))!T5[E*M-?@W1W2"HKM"-7SS?:=LGVL;(J$
MTQAM:P)CW"=.9)-2KDJD%'EL5F>M6A&*<[=[JZ(\NM\LRC),C9U8[I8)R84;
MD29`^.T;HE*D][0ATP]LF\383NAS-8L542%W&;=\&WG->,<\1,-&0F1$$\+5
MJ?R"YH%CLL?$+2EIH%DC$K5%&J-B4DH-A+S7Z11K>(GD&DVU-)P#YX&E7=F6
M]7;OO[P?6-QFUW(;7(V++,YDXHSXL:_@INLVF$4(G.TFY5N92:S59MD%\2T4
M>Q\BV*C*QKV(L]:<2M4FXN7=M*_;>?\`!MV)?\^>4_\`J#"ZU6]B"S'--<D[
M]-OKEY)N:[.4;#>98>.5?.%8>$FZQ-VBE69\S8'/\,VE+6RN%43DWB*95GC2
MHQ#=RHJG'-03VI]MY_P;=B7_`#YY3_Z@PNC0?;_-?^XTM#[,G_B.-B'_`"'G
M7_O19ITI5O6WS[8.GSA>1S[NNRQ"8MQZQ=)1$8DX0=S5RO-H?B5.+J&.J9#H
MO;#<+(Y$QWSEI$1KMO!P;.3M-F<0E0A9ZP12:'LS*9E>AIL2(0QBB:#SGR8I
MS$,!0W2YH$_!BB4P")`,'`"'=^R(@`CIEUU(,FY3Z^7M`=4V6TVWR9<'T/-D
MUM:Q,S:SD0\A:=C+%2S^:W3Y]K49(2+>G2UJMT;CB]Y!8R+%JRE[?3*KBN@K
M&F'%;KZ0&D!\D<?G_HH__=*^Y&]M6;3]VFJ?M.Z;60LH,"&;K5F=R%E\L%<Y
M)H19NF^/*XAQKB_):488!6*@W,VRI)@FHJBHX#W@@R4^KB3VUFCM+^SH^[OI
M]Y(PQ'-42-[-:\:Y8;WVSQ$F[<1RK11?$.0<:8D>,H8(9ZM).'`W^1EQ%HU)
M'PLBE*%.S=W;1MEVVC8QB*%PQM5P]3L54N)CXI%^O`0T,SLF09>+C6<3^F62
M;<U9A-WRXRK%DV+)6FR+OI1P1%)%,Z+-NS:(X\W]].G:UU'\(67"NYO&L#9"
MRT-(QE*R<TB(E+*N'K`_2,6,NN,[<K'NY*"FXR2)'O'4<+A:K65LT-#6Z$FJ
MV\DX9X:7@<\^/Y??CS_7WUE;:]N]V^;U<.0.>]K>6*CE[%EA.#5&QUQV<'4#
M.E:1;YY3;I7WJ3>:I5WBF4S&.96J6MG"V"/2DHMPYB`9OD7!]0.KYU2*]TD]
MK5=W.V;$4UG!A9<UU'#+>H5ZWQE)=,'-HJUYM!Y]S-2$+9$%$&+>AOFX,$HX
MRCES(,RBNV02<."L5?9[MPV6.EGUM<C]./*EJ&7Q[EW,61=I&3VK(DXG5'.;
ML7S]@CL,9CJ<8\@PFG(6VSP)Z1'O'[:':NZ-E=:U6,7!H&(%BXQ]LMY+THL9
ME*H")S[X,0%(?GL`A@Q7GP0.*@>4P()1.*@`(AV_CHT$\$?G_P#8'^^ME:-[
M2WLZ;].2F=1#<95[/@QMD?)&3\9XKVWUV>@\LYCR[+XQF(F,G7U"`[;'T.O$
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MVSG:AFG([#'FZS;5=MH;"R3,/`UK*<+DZ)SWC.+</S/6[Z5R<^+1<462DUYD
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M_L^2R.QJ&(&IA-V%>L<DW6`KMJBCCR`BG+4AQ9H]4H"'<FX.7T$=,%"D`@`4
M.>TO`$+\B@0/<B0H^.2`=(YN1Y$>?)AXT]G]HL6.38%!-2@W,D_W(8G0<%<\
M@4Q&T;=)1$J8@(`54SV/:@4QA`I?/D!X$&3(\\C]PY/V>"''DP`*)3=H"/@2
M@81X'R`^O)O4>J7X)\?#6Z5Y:ZJ#U\EO"ZT[CGEJZ8ROC8H3]A&YEF!''\94
M`,Q?5(_Q$VIK.]Z-5F(AH8F%8UXY^>UZLK.."O!'L0>2?'D``"Z80\Q9)2(J
MU=B7E@L=LF(NJ5NO1B9UI*PV&QR#6%A86,01Y66D)"2>-V[-%(04.X.0"]PB
M*1^BUT^-HD)LOVJXXPF4[5Y<T4AN^7[`T(5%.U9?M23*6N<P'N1*11FUD2-H
M:$$@(@G!0L4W`B:8*HF;7=`#98GEK,U@W@7V)1>T'`<BYJV*6SM-LZ:3F<7K
M,%)F?3*NQ*)VV,*Z_)]E&3,W49V>VJN4'!W,.LB@\N:\]ANY,2&Y)W=PE$QA
M!,@=QNW[O/(>>/'(>-01^,[JM_Q%N:ITYQ-T''[:<6MPO6F4Q7,W9C,M2NOI
MD#^Y4V]28N7[;,S0E!)7#K(WX>-DC'XF?>EROV6<TJU\()E)EBQD7'-HAN"H
MN\`(H4&-8^.]EE&JA`*'84.."_L\<`'`%\<```'H'H```!XX^E;1HU2,!5"J
MHX51P!SS_7/OJRW`Y)^IX[C]R!QR!]/TU*<!,0Y0$`$Q3``B4#``B`@`B41`
M#!]2B(`(>!$.=<T+VO[J9#G+<G3^G9BNPIN\4[3Y!&X9F<Q<@W?QMPW'V*!`
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M_`6VSK`X,B6$95-UT)'X_P!UE(@`1.SP[NZH[$:_84I%L*JK^.C;8:#DHV'>
M2XMWTXS:5"YN2KFR2S5.PC-SP/'KZ?Q'C3H'V<K=O1RY(S-TH-QT]&L]KW4A
MBC5*FS$F@NK)XOW=M4&T9B&TUA=P])"-Y&].T&%?*S>0LDYGL@0.%4$9*(CV
M%CC9V4^C74:STNW_`(;=,;SG&I**.Y*L+<&WMN[)'#DXU!1PT\?,$U8$#]]&
M#W<`AF/U$V?7WQM7)X*1$-EX&LX^4^'KWJX[J\J/RO;RY$4GD#TY&/G@:],7
MQR'GGY<_0`#Z>/G^?GG4VO9Y/QG<,)91R1AG(K4K"^XIN<U2;8W`Q_='?QKD
M5$IAH98047A)Z-7:66&D0+\.O`RK!='W+,&Z2?BP'N`!X$.0`>!`0$.0YX$!
M\@/U`?(#X'7;S'Y"O>ITKE-XIZ5ZM6N4IH9!)$]&Y$EBDRNH[7/PLL/>5/!<
M-]>=<ZY8)JLLE:Q')%/7<UYHY8S%(LL'[J3OC/E&9D+%3Y!.HZM'C<KQJZ:G
M*4Z;INLW,4_DARK)'2,0W!BCV&[A`P`(&\CP(#P8+O5,X%$#`8H&+P(&((B`
M&*(%`Q>2@)B]P")>2@(ASR`<ZV!["4$B=\:RPRR)R!ZD<4T;21<D'CU4)3NX
M/:&)X;C@_/(2H#CWCDA9?^M[$,,;<_\`QR2K+Q_B[.WD$AAT<NG)DH^8-C6T
MW([A87$C/8"QXPF5S.`='-.U:'1J\Z"C@"D]\N$W%217)Q*!O?E,!A$>!UNU
MI(;H2JJK=+K;D*JYW)T9[<HS!90ZB@^X8[L<Z,VB1#'```J+=`$0('!DTTD4
MQ*!2D`%>=<$>HF,APO4'?>&K'FMB-Y[HQ=;Y0O[C'YN]3B^5?`Y2$'CZ<\?3
M733:5B:WM3;%JRQ>S9V]A;%AR22\\V.KRS.2?)+2.QY/DZ^+8[!#U2!F;/89
M6+@J_78J1G9Z;FWR,9$0\)#LEY&6E9.1<"#=C'QL>V</7KM<01;MD%55C)I$
M.H3G[[PO:I-\&\3<2?:3T5,&&!6Q65[5,89;=XX-E?<#E$T(H63>WJDXQML6
MKCW%-"6B(V>>3)LH5*]R$3C]NK>+4^Q>\:R\/7'KW4/QG=<T[`=\>&L:PI[)
MD;+>S[<SC&@5U-TS9*SUVOF%+O5ZK"INY!=JQ;*2D[*,&)'#QRW:H"N"SE=)
M`BBA><U[))O"VK;1][>>:MNAM53PY9,Z849X\Q+E#)4J%7K$=8*[<F]@M&*9
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M.678R<9),W*+IF]:JJHJI*D.4_WM&D)'U(^_G_O_`#UCXD1,/O98>EU(,$7"
MK&NYU6E9YZ@4YFT5%R-JW@U9@]D0(50@-`LMEKD>`KE%,)!XR``%?W11VDZ9
M_1FV4;\]JT+GC*-JS0WR4GD#)M$N<=3)[':$!$N*G<I0E4:-$[/B^W3`'4QY
M(5!^[4<S;@JB[T01(D@1$A=M>DGMJCMW_LTNVK;K(/&T.XR)AO)Z5:GW38';
M6N7N`W%Y&L]"L2Z(@*QD8FW0\0\>%:"1T=L"Y&RB2@IJII_=*W?I*],K,N8M
MI>\B%LV.J3.6IC)V0@,9>:=X0RDSBVT0M-'@(6.D)VP8ZR3!-(1[^D<#%OV3
M<D;$2;9)U%.)5PWN1TLS>Y\O^'O=NV^G&3NU>H&SMZ5=ROBL7+''D\EM^Q2-
M288M&1YI)(YI+4U@UD:0+1IQ*>^[7CEKUO;'8FCU5PN5W7CHKVU=P;?FQ7Q%
MB&26K7RU>QZT`OLO[N&)HB54SD1`R=Q_@8A4W_<RO3R.'(7'<D(>."A:L.=H
M!SQX`<%<?+CY\AZ^-733V9_8&Q:J-6.0-T,>19,45#Q]YQ4Q6%,RGO3E*NWP
MNFX1!18`6/\`#JH_K`Y*)?32O=6WG[/[37FEIKNZG;M+U]XU0>)2S?,U!,V^
M&<%]XC\29S8B+M50[NPR#PJ"R*A3(J()*D,D3#=CZG>Q>&R/CK#<-N-I>1LH
MY0OM0QK4Z7B$\GEN3&TVZR1=<9GL+['<?.P=/AXQ23^V9^5M\S`L&,#'R;TY
ME2MSI&B>'J)^(V>:TU7/]2'GQT+RVRT.8_N$,?!M/=DAJE*M>-%5FDD].(JC
M/(2J=RO5]I](*XA5,9M./XGY:\,5BE&UH2-%R%B2RGQ+"3TPO`D='=1'VF0A
MDWO:3J=%8\]GRW:4""5>+PE'JNT*GPRTBLFXD%8JL[K=N4+'K/UT46R*[Y5J
MR2.[62;-TU5S*'(@D4W:&E?L5?\`BL\\_P#Y`<J?]W+:OK?WVGX#N>A;OH30
M1565*3;8Z%!,IE5?A6F[[`"[EP)"@H/N$6R*CE=;@4DD"F65$I0.(-ZO9'^J
M9LOVP[:MQ^T7<QGK&>WBVJ9V>[C:5:<O6QE1J9>*_<,>8OQG8H.+MDZ$?46]
MCI\OCR%?'K3^PM)^PQ5K6DZW&RT54K6_B81>5YY))Y)&EDFDDDDD<DN\CNS2
M,Q/DDN6\_74FHB1QQ11`+&D<2Q*!P%C15"`#Z!4X`'VT^/W<?X+>Y+_H^YK_
M`.S:QZYQOL6*2"W5-S<=1!(ZC3I_Y6504.0ISI+FW&;84!71,8!%%46SE9L)
MTQ*84%%4Q'L54*+\.9WL[4]X^U_?$.US.E,SQ'8@PMDBN7VRX\=2E@I45,V3
M#MIL,3&1=Z)&I4FV.`B!(XE#U"=GCPSA0D=83Q[\$&QF'_L5@#_=2L[CP/']
MS]RJ7GY=P;CMK!A#GZ@4Y#"'T,4?F&L=>FNGJ81`.0^O]NM%NI_YZ:O40'Y_
MU%-VG\\!Y`'6]!P$0\!SY_MUHKU/SD_N:O41#N+R38INU[@Y#DO;@&_&-W!\
MN"J$-YX\&`?0=!YX_P`_]QS_`"'\M!YX_P`Q]/S'/^G\M,5/8E`_OT]XH@/G
M^JU7?7_G3JWY?32B/MO/^#;L2Y_X\\I_]08;\])W^Q*?X:6\0?4!VM5[T\^F
M5*P4?3GR!@$!#U`0'2B'MO`";;=L1`H"(CG/*@@''D>*#"\\!Z^-&L"3R.?L
MI/T\]PY_KZ:6B]F2_P`1SL0_Y"SMZ_\`2BS5_L'XZ9%^ST`P@/:2J["W^/=/
M+N>_[YX&&<+)&;.(C(##&V9WD[)/6RC=)1N=6LQ=UB3I*$;*)N9(I#@F)?<G
M>W^S+G*7H;[#P,/:*D)G5,@&$2&,8VZ'-8_<`1*8P@0#*`!1Y,0HF(/'`Z9\
M=?W:#GOI#=6ZG]47;U$S2.(,U9T8[G*7<?=3+JKU?<O]IJV_,N%,AR*$L>1*
MSRE*%LUUCHV33JS"U8]OMOHU5:2[?&=R49&E!!+#]#_,#_Q_/73K;CW(IB''
M`E^Z)1*)3$Y'L,02B)>PY>#$`!'M*(!R/'.H+]W:7M[_`"<`$"@40,`<G$A@
M,`@`*`3W?=X$HG`0\\:1#V.>T"=,/>[C6K6MINCQ?MXR=(,63>WX%W!Y`KN+
M[A5;8Y0%Q)0<)*W=Q7H')L4@=NX7B;/C]Y(-7,:NT+,,ZY-G=UR*QEU&/:-N
MG)L>Q);)/'^X/%6Z[<,,!)!BW">$+DUR3&3%I24BFS)3(^0J&,]2,?0D0[?-
M9B7"=G8JSRD*TET:579V6;.$$S2\$`#Z^!R!S]M,P][*PY`]K?C@Q9+-YB2#
MJ5;.(9&1K+M$Z49.45Y@6(O"3A=K[T$GE3F("T,+00P^]92$)*I/4O?-W"(N
M<?;-^/[D_C/GR']=_$G(?4/Z)MP6D0?9<=@N7]Z^_P!R'U==QS5U/T?%^1<J
M7B"MTG$PY&.<MWF5%)AQ8)AE"R46*:T)C=*\S.0%IB,2K;B#R8ZQN$(^4-#6
M:-CEOO;,1!3I.XU[1`_]^]B(`X'N\CB?/P<>.?/(\"'KR/`^=&D]R/T_3ZJ?
M8_T-9"]C_JT/#='N.DHYJBV=73<WG"S3ZB:*13O95H2G4U)=P<0-\0?]'ZG#
MQYE%"BI\,V20*8I$2:=,%#M*4O(CP`!R/J/`<<C^(^HZ;$^R)B`]&NA@`@/&
M>\\@/`@/`_I*R'@>/0>!`?R$!]!#3G?1K(>PY]_KIFA[;'_B]MK/_3-A_P#L
M1S'I0+V4_P#Q(NUG_P"[=R'_`'B<E:3]]MB$!Z?&UA,!`3FWF1`E)_PC`7"6
M80,(!ZB`"8H"(>@F#GU#2@7LJ(]G1#VKF-R!36W<?VB(#P/.XO)90\_YP&#_
M`/4PCX`1`T:V`]H#J;BQ]-R\RZ':"=`RCABYO5!!4PI,OT[C:FJ8A42F.8QC
MVM)'CP4"JF,<P%`=,D,:XWO.9\@4;#^,HE.5R)DNSQ=*J,=VJD9HS,PY(@23
ME544UCHP4,Q.YF)Q^4H@RCXF0<J""9"B'1\WK84+N.VE[B,&IMD7,IDK$5XK
M]6%=,52,KR$$\D:#+E*4Q#^_A+HQ@IEJ8A@.5TP1,0Q#`!RMU_9V=E[A<EGW
MV9%KA4738D[A_`3.1:%$\;\`883+V1V*1P5,@O(R;$^-(9X@H+]N@TR"S<":
M,DDBA>GH!UFQG3?H3U"DF>&;/8;<0.!QDLD:M>L;DPQJ8Z58BPEEAQF3IR9"
M9HU9%1&$H=3V&LG5'I[=W;U/VK!")8L;E*$LN7R*(S?!PXD]IA1^TQ+)96>,
M1JY#NYX7P>=./]L&W2B[5,$XNV]8[`YJUC&MFC4G[A$"/YV?DG;V7MEPDTS+
M.!1E;99Y6:L+TI5U4RNI9VB@<6Z:(EV&(3L#CN$WXC_I_?ZCJ($+R`\!R'`]
MW`<B(%$O//S\"(?D.IM4=N6K&0NVLC=F>S=NSV+5NS*>Z2>Q:E,\\TA\!GDE
M9G)X\=S!>%/&K*5JT%.O7J58D@K5*\=6M#&.(X:\*A8XD'T5%4`?7@#DGC4B
M@F*01(!1,''`&\!Z\#Y\<?F(\?75J=PH0Z9`*F(G,8`#D>>TI1,(B//!?N@8
M0[O`B!2^!.`A7<&`J*AA#D`#D0Y`O@!#GD1\`'U$?0/.DM^K=O:1V4;3+/8*
MO)H-\W95%_C;";45B`Z:SKUBJYM5Z22$JAO<XSJ2<M:43J(+-'%E;5N$?G;-
MYDSIO]^W\!F-TY[#;=P5=;64S.1JT:D#!V5O6GC6S+)Z89ECJUB]AI.`D:K)
M)*1&C$?+E\I4PF,O9>\ZQU,?6GLR$NB=[)&2D3%R%42.`D9)4/(P0$D\:8]>
MUI[EYW=GN!K$7CV97F<!;.75CQ/((QYQ=-'>8[?*J#?KXBNR<`U<0#%U4X'%
MB2KMH8\3)P:CP'IV]_AP.SE.GV`''O/VN`[B\%X`H\@/CD#`<!`0'Y>?GIT+
M.5&'ME;G*19DQEX:RQBT#/BZ/WOW:KA8PO951T_*=9617DRC-)NW1E'*4F5)
MRHNHX0!?3<#+5`F\67^S4&P<'D("1`A'1$`;HR<<\;HOHB9;(%,<$6\Q&.FD
M@FB)Q.V%R9JH5,Z)TRV:_$GT"I])(ML9C`"Y;V[D*4."R%Z1U8INW'0Q22RN
MCR-(E?.4'>^BA1$D\,L478JB,1)T>ZFOOV'*T\DRQ9>E8GO1P_(I;&6K#M5B
MC6-$#BF)%JRNP[N!7[F>1I&UC40Y#Z?^'G7TXF1>1<DUDF3UTPDF2Y'T7(LG
M:\>]CI9J<B\=(LGK42N6CM@\(D[;KH*HJD61()%2"`:^=VF]>PW'=V\\>.[Z
M?7GY>GKJ'S`0$0$.!`0$0'U`0$!`0]!`!#\0`=50/(+`\@\=K`^/'(/!'Z@'
M@_8:FOQ[_P#4O\^.X?R(Y'V(Y]]/T<OY5B>J#T\MO?53K#1D?.N*65;VJ=0^
ML,U$'JS>]U12-8T#-CYDVC6ZT=$749%%=13[R+*)R7"4]&2DU:#(2)TTR^`(
M`'.H7M+PJ=3WIU?'`'.H8.5#'X[C*"/)Q$3>H@&M2O9[=^=`VD;O)G"6Y)VB
MYV7;[*L;;5N,BIEXL6LU]U.$=-\4Y0E&RJ[:+1+4;-)O:Y+6%^N`U&AWBZV1
MJ15U%MFSE2G=#MSMVT3<-E#;?=GBTG)XWL'PM?L2Z(M!NE`DFC>1H]R%N"BQ
M$S3T`\(9TW:N'`M+%&S;1XL=)FW(7IU^#3JJ,_MZUTUR\IDR^UT^+P#R,@:?
M;+DO;B3AP\LN(NM&D*E2PHVR`K1U2RTUZ_[+;$YN'=]%`,5G`*N4X#?W3-)Q
MZ<_\/"I>C6-!RQ5YEEX`+*-8.U3,<$P,J?CM3`5#!R(<E3X$?//CD"AX^?R$
M/E.(@'S#]P\\<`(^0#S\O3U_#7T8*I6/(5DJV.J:V!Y<\D6NLXYIS$QO=`\M
M5ZF65;KZ!U!#]4DI*2;85UQX(@@558Y@*F8Q;N6;4%-&MV&05J8>U=:1PD4=
M2M&UFP9W)411>E$S/(S*%4%NX`<BO:Q&:2*$`DS35X0O!+%YK$*0GM`Y^28Q
MR#QQW*`P()!Z`G1UHA\=]-7:'!J(&;*S.,Y+)"Z*@+E5(YS!=[-EAR8Q''"Q
M167NBBI@.4`*(@"7ZOQI337@L;4>'QG2*5CFNE.$#C^E5FCPYE@*5<8FIQ#*
M#C!5!(A$/>G:L@.L"12%`X@<"`50HZ][K@)N?--N/<NXMPR,6ESN>S&8E)7L
M/JY/(V;LI*<+V]SSLP7M7@,/E`X&NG>"Q[8C!X3%.W>^,Q&-Q[M_S-2IPUBW
MN??T^?<_J??5NZ2462`B1RIF]ZB?N,!AX*FJ0YA*`"`=X`7N(!P.F)P`JA!*
M(\-_]^'LS?2ZW]Y+G,TW*D9%P)F"Z61U;,DW[;%;8*A*Y*G9%-TI+RMLIMTI
MN2L;_;5@EG:MCL]H@:;!7&U64Z\Y9K',2#^45?N"-&M'K:::`C[%3TLP`>W/
M>_X1^0#E3;J`?Q_JJ#Q^X!'2V.Z?HY;'=Y6W7;CM8SI1;5)X;VJ1%=@L-0%4
MOUBI+F%BJS0&.-HIG)O:VJP++D;UN.:I$,HU0`BR("BFBDN\2<JFZAP'X_Q'
M^W1X_H?^?U_KV0J&XY)\?;C\OZ_R&M;-J6UK$NRS;UC7:_@.+EX+$V)&,S'4
MV+GY^3MDPU;3]FG+=)%=3TRJK(/NZ;L4FNW!8XE:H'09-DTFC9%(F.=UFP/:
MGO08L$]P6*8JU3D.@HW@;M$NG]4R!`)JCWD1CKE".6,LJQ;+A\2VBI)60B4G
M(?$%C^[N$=UQ(4P"`@/GU\CSX]///(?Z/KH!,G`!V\@'IR(C^_R(^?7]X\Z^
MO$Y7,X#)PYC!Y/(8C*UW[X,GBK]G&W8R>5*B2JR-V]C,A/?^\0LC#M8@_#DL
M7CLQ3DQ^4HU<C2E`$E:Y$)H9."K`/&?!`90RD$,'56!!'.FZ3SV:38T]=JNC
MYIW@-TSNA<-V@W7`K\K(ACB9-HUD);;O)SQFR`&[$S.Y5TZ$@`95RJ?N..W&
MU[HH;(]J-[I.5:9%Y2O&3,<RBTM3K;DO)<B^2AI!>-DH91ZG3*7'T?'"[DL?
M*O0057IJBR"XI.&ZJ2R95M*Y"@01Y'O_`'',`?+Y`(!\@^7RU4,0I@X$!$.>
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M^\1_EXU$P]H"/T_T?/4;?8`#P`H`X'('@?8<D`$_F3Y/OIY<LW!8`$\#A?8<
M#@`>![`#Z#25FP'H_;5NG+M>R]M*PM,YDN&-LY3=OFLCS&5KU$RMVF%;I1V6
M/)1NSDZ-4,?0T&W;5=@V8QQH:OLWZ*R*<@XD'3TB2J7G-A'0\Z?/33S%-YWV
MF8[NM.R-9L73>'Y^0L>4KI>(Y_3;!:J5=)%+[*LL@]:-Y'[=H%>40?,2,C)M
MRO$13,5R8"J@9!N+?'M'N5^?M7\C'4:H6:X2$=&?"F?R+.LPSN:<,F/QJS1J
M#UTW9*HM1=/&S?XDZ?Q"Q$N\Y4_^GQU.,4=1:,R2[QG3<EXWD<7'I)YJ`R@2
MB)S$G'WDDR>(EXI.G6JU-ACO?UZ28.U':S9PFY]T!6@`JF93;5L!G+V#S&Y*
M&*N7<'M^2M%FLE716KXR6[)Z%*.TS.I1KECMKP<*P:5U#%5Y8:RQF<94R.,Q
M-BY%%DLPMAL;3<D2VOA8S-86/QVEHH%>9P6'R(W'+<*5-]8PS+B6IYVQ/E7"
MM_1?NZ#F7&MVQ->6,9*/8>1>4[(-8F*E9&\;+,CE<PTDM$3;TC669A\8T6!!
M9`Q%$2&!-O#75WPQFW>Y/[':AC_*9K;7;'E*MFRD\4QVXQG,.L4QTD\FG4>>
M)MCNVF8OE8]5LP65K*)17["*J)%!0P8D=];6#=92SMBK&FQ+?WGZ4V_Y<ON&
M;M-X/Q54,BUU*Q8_O]HQXYD06KUO6E(J/GW]2E)6')8(Z-=&CB&.X;-S)*%*
M[/[*>H8M34I-L6JUFMBL7G+<=^YB\8M7$YN9ZV*O3S9*_4@CAO6D%:$-)ZGK
M.B.B?-VZ8;YVF\*68\W4FK2Y27#PSP>K,DN0@JFY-#&J1F5BD`+\^GPP'<G<
MA#:S=T^^BSL-Z8^0+SDW:71+M4[9D2G-J%9W=HR=<+PU=UMM,,[`1!O&S[Y9
MBR=C+,6JPO4D3KE12.@B=%-TY(?*/4(Z7>T;J>UG&M/W<5.V6ZOXGL4S::@Q
MJ]_L]$!&7GXUO$R2DBI6WK4TFF=FT;E;@X#WK(P+"U63([=$5Q3>^J9$8JV8
MO-Z>6]KN[#$T&PR8SQL\PMDRCUFA9C:JOGR<:SMAX.V3<1%#5'RI_?,'QYLJ
MCT/"")C`*88-DNN#"4=DWMF;>GQU(L&8N*X8MYG+60L!QK+'U=:R"S=!K*RD
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ML&[2TM6#V/LDZ:Y3-<<,XY!M)%^*CB-%;`U=,G;-Y$(N45DDOO;S^H]A?91-
M4:AVB)R9F#-^4"+CC;`.#ZB6ZY/MB*#H6A9`(L%&C>.9O'A'#*)*Y=`_FU6,
MG]BL90L1+J1^L@V3N^TV(6MMW)S#/-EUQ#+$@6Z<!-6KYLCOD4U4Q<UA8[LM
MT5HH3'(6?M4,?KL[GV[0CR4MG+TXX,5'CI;TP9Y$C&61#C%011O).]Y645A!
M')ZK`J#W#@HVYD]CSZ2&5;T]N=7D-U.`8Y\@"9\>X<R[3GU&:NA<.UU7S`N:
ML3YAMK-11-TDR38(6PD&Q91[%.,B6*A7*KG[N`O9#ND;A*YM[?:6FY#<JT8+
ML7\;1L_Y9KRM#:2L<\2>-Y)S"X9QQAMW8`4%$K1]#6N3GZQ)QYUF4C!.FZZQ
M%%:=J^^[)FX;*CK&=]V&;PML+4:#+7V+R'FJEQ#7';T8N7JD8E2GD_"/7P0]
M\DFMH/-,:^[(<JD?`3P"_P#BV"S4,:[\.KI@[87DJ`QC<Z/EC*5CD<?CDZSH
MXJ:4MXTQQ3E+$WK$)*7,]CLD(Y:I6657=D9`T1<*>[CTC$2_WXD"GK4V'O#(
MY]=K8[!39'//6>Y'0H7,9<]2I%$TL]@6Z]V2DL4"JPD:2RG$G;$O=(ZH4M;J
MP%+%?MRYD4JXH3?#M;LP6X.V<R"(1&O+`EIG,A"@1P.2.9/_`&E:0*:TZ@U7
M'=3K%!Q_6ZU1Z)286/K5,IE1@8RM56HUJ&1!C"5ZN5V#:Q\-$PL/&)M&$5%L
M&39E'(L6I4$3`D`:U4WY]/?;;U),-PF!=U%>L5GQM7LC0.5HR-J]QG:-)?IE
M78.U5V.<.IBOKH/7#`L7<9E-1D)P3.LJ@Y']>T;J)W^Z3>ICK:WM(GMY4BSG
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MWSYY].?&M6=X^ZFM[+]NF0]R-UK%ON]9QTM70DZU125X;0])8[3"UAL#`+++
M04.(-7,VV<.O?R")S-2*"@)U@`IO+&T;>7OX_&8Z![5_*VJU*A6C*A[-JV\<
M5:%"S*O=++-'&I+!>]@"P'G7M;MUZ-2U>MRK!5IUS:LS/_#%712\DK<<_+$B
ML[_4*I(#:QIU`^FKM6ZF^.J+BS=C6K5::9CN]#D6N1]5O%@HRY+-^CLU62+O
M7M?70</&Q(Z=>^[0.<HIK^[4(?L]\BODO9GLRP=L+V_4[;#MTAIN`Q%0I6W2
M]9BK'9I:W2S)U=;5+W":`TW+J'?J(C+3TH1LD=4X(M%$R'%90RRA].-UW5ZQ
M+M,PMM5S9:<0YBN$)NRHCF^TZ$J:V-TIRKL4*;2[DC&VD;+<X2,/)/4+M&Q;
M1&!?RX*R*+E(IA[VAE]ELC[Y<5T391-[[X(LYD_#<9C"*RI'M*8I7`LDW#RC
M]BP5BFWVU)1L"UGH9T\.PF6,A-,P8/V#^/<&(]0,4'#+L7>,-7!WI-N9%:.Y
MLO+M_`7.V$U\GFX;KXZ3&1.)3Z-H7HIJZBV*Z.\,I1V5"VM1#NK;MBY<Q\.6
MJ27<?1AR=VN&825\=/7CM1W9`ZJ/AS!-#(64L56:+N4=WC==RF=0@%(;L-W`
M(&`!\"'D/)1`?4`$`^8AY^[W`;X5?K4'589M7ZS#Q->AFAWAV41!1S:*BVGQ
MK]U(NA:Q[(B+5L9R\=N7CGW*904=.%UN!.H.M&\W]1K;[MQVQXMW/YAF;%7X
M#,%9JD_CW'C&+C)G*MK>VFLL+.VK<)7V,DK$NI6.CI)$;!**S;6KQ`F1^)F4
M`=,E'6$L+=37)N6,D8RJ<[TV=_\`BJC94G(^$A<LWC%\(%5JJ<HA)JQL[DQE
M&OU96CUYPJS1:OI9T5VV9GD898IU&[Q1?20[$WK:PV0S4.&LQ8*ED+4,U^S9
MHTHK$N'0KD8\9%=MU[.6>K8CEIRC%P6VCM"6$@$\GR.ZMN+=HUOCHGR5R*I)
M7KQ06[$D<=^**>NUMZU>:&FLD3HZM9DB0J%969>#I74/`!^0:CJ`>0`?J`:M
MES&+W=JON_NDX'@#=OW^.>!`?VO)1'\O3C35^WU)]A]2??@?G^O&G(20.0"Q
M^BKP68_15Y(!)^G)`_,:B]#EHXY5(@`)',*ZABD(B!0[A6,8X"0"I`'O!$X"
M3@OWP$O(#SW>JSO,'>MN\LEFKSU%]A/#0RF*,'%;G4,QEX-HZ;#=<@)&5*<O
M??[8Q73_`%"30K^HUJH,I,AW+%P4'+W7,WO.MM&U]3#='FTVV8]S9)JC-3,7
M:"4M3,1"S=,LCWI(IFRZK9U(MW+&A02Q3M'S:5M;F?@WJ+JIN5F['EHBBD@D
MFBF5))---ND0I`+V(-TTTT$@`0$0323X*D3D2D#GM`HF,)NB/X)^E2CXWJWE
MZG<7BLXC:*3I(@)X$>1RRAT[2JF26A!)$2XEAN1N#&RMJI_XBMXF<UMC8ZR%
M16BO;@DA92QX!>ICF*GGD,%L3(W"A9(V4EAQJL``!>#!W^>T1/RH*G/=R=8#
MB/<=8W*BQ`,5/WAE"I@1,I0!/GJ"X9/<*/%Y=@VBJUAH!!CK8<O<NO(U"0D%
MG"$@L(@9?BOR[ODW:4Y`92SYTN=--F`"H5VAY]?(\_OYY_/\/_'SJW=LF,BS
M>QDHR))14JR=QDFP6*J=L_82#=1J]8._=+(G*T>LU%T'9^_DC45C)=C@$5"7
M-ZC["Q_439N<VIDXH&3*5>*EA_4+X[*5(U3%WJX1';U.^.)+1X!].28+Z@^5
MH"V9N6YL[<F+W%6<JT`]+*5DY]"U5DE#3QC@=Q`B+%6*`K(J-P>WD-9SB(&.
M0!'@!(?Y#]_M#GM$!.40].TX&`IRB!_0>-6X>0\?^7X?NUGG<-AUYA/*]BI!
M@45A_B0EJC)K&.<TA49$ZAX=50XF.D9VT;E^S90A0,#:58/6Y#&*ER.#01#C
M]KU_^D_J/D/^!_'S^\-</,_@,EMK+Y#`9>&.MD\3=LT+L;RJKF>!PIE'JF-W
MKRJ5:O(44NH8]H/@=(L=D*V7H5,M0ECGH9."*[5FC)$;I/&CGCD<!U!0.@)*
M'Y6/*D:$3)%`?>E.8!%0#%(8O)@.D!"B4H@`]Z?)SE$QCE[NW@@<&$[YK$N:
M0ZLO2/QYN"<S"T_O@Z7L;%84W6$D7K]];,H;4UT'J^/,TR"RDJZD;$X@H]M]
MIV6=L#US(2%AJ&=;&_C@/+54SIC."7'H?@?(<]AA^7`^J8^!#T_D/KI6_HN=
M0Q3IP;Y\>96MYF\GMTRE&.L![K*F\B$)-E/[?\B/8MK:)12.-"23UZZQ_,,(
MB_,T(5!M+V`*O(T8D@E#6^?1?;?86[<IL7=N!W3B)2MW%7XW>*&S`IN4I"L5
MNB?WH5A=K235W[_E'J+)W!D4C5;LVY4W9MW)X"[&ACNU62*0CN,5Q`'K6>5^
M8-!.(Y%[>2W:4/\`%X4L((F3(H42'(=),X'24!5(W>FFJ)2*AP4XD(H4IQ*4
M.%.]/CN(.EQ^@?M1<YOW=.=P-DC%5,9[5V2LA'/%4TC,)G-]P8FC:E`E64[S
M*_HC7'LW=Y!HB<BD9-NZ&\.3W3\H'TLW3;$KYBS>]_52P9%*9%B,U2D1<=IL
MC!2+:9C;UA_(Q#24!+(V`J[ELK%T%)&99W"Y*+/(QK#5EY>7*3J)E6;9!\?L
M7VCTS9/MKQ]@>I':2LG%MQL.1K<@W79J7W*%@2:J7.Z+-5W+QTU:2#AJ#*`8
M.'SQ6%K$=!07Q+A.-*L?HU^(_KSB(.D]&OMG)UK&5ZK8:J]?X-P9*VV)8Y*N
M9MS`D2TYII8YL.L4B+*\WQ3IS'`':HG2/IE<M;ZMRYF"9:6S,I(9!8CD"W,A
M6;LJP`NBI+#'(PM$\LI$*`KPZD[@H<<B(B`F'O$>/Q,'/S'G@>/(^HB(ZN=4
MR))ICR0.!X$/41]1`1]1$?4`_AJIKEBB]J@$]S<#N<@`N1X[VX_Q,`"WY^!X
M`U=P$GAF_B(!8<\A6X'*J>!\H^G(!T:-&C66C1HT:-&C1HT:-&C1HT:-&C1J
M4_/:/''/CU]/4/SU-JFJ8I"&,;T#CGSQ\P^?`_Z-8LK,K*A[692JM_RL1P#^
MH)YTH!)`'DD@`#WY)\<:P9N1$P;>,^=Q1[!PME4A>!(7@3T:;`O(J&3`HCSP
M`B8"%YY,8H?>TS9V]9GENFU![,MXD7'HI4C=%TM\B8UE8\S5\^BI'<CA*:DY
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MTQ:8.%9NR7&"[`WIA7[G3R4##3>/8#@22V\[_.E;5;.4H9)R)LASOGO*TX\^
M&)99R^9IFLGW)8]@64='=R<O6:J_K%1>NR"H@4L"=P0C=PX=@I]7I]8ZW-WS
M>CU=`VX;LZYM7/'[SLR*VMQ8,'TS,GZ<"\W*[ID8@C`MML$!]EA6UHQVL[^#
M%T54)KX97W)Q(H1SC.;:,(67/5*W/RM)0<YRH%-E\>4^\A.V=$\-3Y@)3[2A
M$:XWF4:FZ1<C-R8F7?P3I\4'1@3=$*5,$],\@=&7IGY.NEVR#D':U`6FWY#N
MUFR+;YIY?,KM1E+I<YZ7M-DG`9,[\VC6BTG/3TO)&9L&;2/:KOUR,FC=$P)E
MD#^WS%9J7/MN%,C!;SVQ<-MJ]8;;>T]X4(,G0ZA9+=WIC"[GR45<T8,;?6OC
MTX@>JPB6$".(%VTG3++8R/'UL19KI!C-T6<ND?[1O8<OCEVG!A:JO:J1R'XB
M2_$)K;)"D4P[NY2QYUHCUNH:\P?1R?P>4LK1V<LC1F0\6-+5D^LU>&I47<)H
MMTEE@<MZC`2#Z&B%6S%9O&*1[5ZL'O&*#U8Q%5#%2WIWMY[V_P"*.G3DD<RW
M*E(Q]MVMR-1K=-D9&'E)B[VVP4!G`04/!5@BSR1FG3.PSE>=.W[%@HC6&J@6
M&2=LHEFN^0RHATT]D4=MO-M":X%B2[<UKF.0U<9DN5^;LOTT5?$D5)P)DUL&
MV`H9VF"IF(3@QJO<<AF@I'.0V-*5T:.F1CVS,+3`;0\?N9IBLW?(*6R3N5^C
M@<M%D5VJ[NO7FTV.)?*(J(IB4[E@J0I0.B!?=.'*2S-QV].FDF%VOBLK-O:4
M;-W_`+CWOCDP^+V]1GSN/RT6UACJS-'N.<[<D]7`V1).E7*PU_4C>&"7TW0;
MNUMO=RY/(7Z$6`=,YMG&;=L"_E)ICCIJ1O)/(8TH'X\^ED)F6)WK26'`5GB+
M%@W!S;4[E1^E'T4HV](R#&:<[J9NX1J+D_>Y)4[SD*]7;'*"(J*J@5)W1)ZN
M?9:::IFY/>LD$U4VXD4*I'D2UT_!?M$[*\[C)%E6JIEC;='UC;=<[:Z*QJL1
M:C0$+6G#1K(OR_9\?(*RS3(\$#I)TQ,V<WUHV=*"2?2$RY>X/:=M^W4(X_2S
MY027X,3W5MD.A"O9+97SUZWM$DT&\R@:GST`JX.D1$A0:R`O&(]QP4:B"AP-
M<;A=K>W_`'5U5&@[BL35/+M8:O%Y"/;61J'Q\&]<@@5=S!R\:HQG8)5PD@DB
MZ7BI%DH\02!!T=9+[@[P=<L7=J0T[V)RU8;BQ75[$[JFQEO&1KC(^HV;QV=J
MG;YEF_?RU9:D=:U485TL5O7@6Q&LY*Z^/II?II*<3;I&3'S;#GQ`NB2&KD!L
MJD];X;)(H9HHI)9YYU2,RR)*L,H_A`&0\AY,HN*ZU8+9?[)'0$-5ZA:;W/JN
M7R8NV=2IL,XF[3.MXM);[;DF\-'-^]T$4S>+IG7;)E+W*<D:'X#PMU">H*SW
MF;SL;XGVIS=(W^L;M@]-SN4NV38VZT[$E-D7]1;P^*H['#9&,@U:M.UFI0B\
MY,/'L@7(>*4YA@U116<2KY=V@]$KIA8O9Y`8T?;(6$1R;25L<793^EW.<DZF
MZ,YLU;N+ZN$?R>3WC]BQD9^I03B45BW+)W),VJT.^<KPSY_'N%$,38DQUA#'
M=+Q-BBLMJ;CFA032N5*L1ZKQRVAXIDNLNFF#F4<OY!\NLX<+KO'TD[>/W[E9
M9V]=.7*RJQVAMO?&W>FM#--LFKD=R9W,7<15%[=.&JXRG7V[2F3+SUTHT-R7
MK$,UK,4L4947(31FM5EB;DV9$7=YC:^6W;>Q[[CL1XK#XV&U)%6PN0-NS)E+
M0^#BEEGFQT483]G6+?*BLS"6?D,I565H:]SU.Y`Z`N\/;1D5.08Y@V19HP1@
M.R0TJJ\>2K6AQ.\C$S.BE4*]]^HV3K:45;,8M(WE52&3QTDB=%,"H$%T%L=D
MXTNS7:4U"1C_`(EKMOPBT>-Q>M071>_T;U5L9HHB*WO$W!70^X]R<I%`7#W8
ME`W:4WAK?TSMD-SF<\SMBP6P?RNY]Y7GN<U&=UR'"MK\\J5[@<F0+U[#Q%N8
M1+-^SO=9B+(L^A6$8[D'R;P)!9RWEI9%[A>N]$WI=46V5+(U:VD5N,N5!MM7
MN]5GT[IE5X[AK+39V.L-=F"HO,@+M700TI&,7I6;Q!VS62:%:JLW+<YFY]WO
M'?O3G=^$RM",;DVTUO?&8WM!6I8#'7\8EG<>W=N4<G4B:3<>.EAIP9G%Y.:B
MD,5CTJ-BM'*PEC8:UFW-L[RP&3H7?2P63CI[7K[=D,F0LPW'-++96>O*_%.8
M&5\98QZ3,Y7FRDK*!&572J:2Y0,9/R)TNTARAQR'><`((")N!`P@<I?(&,=)
M5,I3*$,722773,8>EWN2$I%3?KL1")2D^\('S902%Y((E.4`Y*8PG*4./41[
M3=N9M@FQ")V?CN(OD_<X;)^=]TF<;EF++F586G$I;>32FI:6DJS3(N$<V"W+
M,X&HJ3LP[0$TNH9Y-3$HY!)M'BRC6NV><\`8CW)8RL&&LU5-*\8SM0Q!IZJK
M2<S#(2!X"<CK'"F-)5N2AIQ#[.FHMJ]1(TE$$SF`Z+@BS8_N=1K@\CA=G[[V
MWF8+;9[";;SN$R/Q,=26FV2@QUVA;M)%4M3":/U/AIJ\'KR1,W"RR>D9`J/+
M(4LCN':F3H6ZHQN0RV+OTOA&L"9:_KPV:T0EG1.)!Q(CR,L9X4E5![06;6[L
MXJ'LD/[-57+'&1<W7[+(X;@)V%FV"$K#S$1*T[:_&2<5(L'`BFY:/VRZR!D5
M4U&XN#HJKE4(0$5M6MT9K3TR,9;]>FC>G$Y+;7]Q^-;?F?9#=GOVC8!K\LI:
M:Q^D6&G;]0SA!FFV&-42E&Y$419V`8NUE8HLLBNW$0ZHL6RO;/<`VR?I)C)O
M)DV;/85_MO\`?6>XH?T=O*TRK3&$72*SL3<M@,P1I]=*F2WA/I&&/(HJ0ZBK
M@ZWT]R>T#;CN^J<!2]R.,HS)\#5[&%GKZ#Z6LD$_BIQ2)=PSA9M-5"8K\RFV
M?,7RY9&,(_")?+`T<NV"SB.CU6LT8?KKMZ&SM;'Y+#9NUM.I9S5W<="/X>/(
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MV:#0KE:BD(:`:$"9.\?"]AX]HB2/F/C!FVRQ`>)/P=E(L323%?1HZ:6$LM5G
M.^-]L+"$RE2[$C:JI87F4,TV-M`V)NL*[67CZW:\B3-62>LUC@HS5/"J&9F`
M`;>Z```6'N/>>TMYX/#4,S-N##93:D&XX,.N+Q>,OXK*4\GN3([B@7(3V<_B
M;&"NQ6LI+#>L5:V426!49(V='+.K$;?SNV<IDIL>N&O8K-1XKXU;LUR#(4I<
M;C:>,`@CAIVH\E7->IZD-=9*4D3N8V9E+,%%83*&-K-:;-1JWD"DV&[THK<]
MSIL%:X&6M=1*\#EH:SUUC(+R\"#OD/A?M5FU^(YY2[@Y$/K6>P0U8A9BRV-^
MVAZU7H9_/V&:D%2-H^)@X=!20E)%ZY4.0B#-@P1</7:PB/NVS=4P`)^THX.Q
MYM6V^XIS1E_<70\=,ZYF;.S>$;9;N2$[9'SFW-ZX'NX0CF+D9EY!1P,2_P#J
M_L:)C3JB/Z\ZHF'GRF]_;3)[PMLN3-O,1D^=Q&XR+&QK(]P@6+&4,>.C)N,G
M'5:FX]T9N[=5:UEC0@K.A"R41+.(AVZ:$D`:.';5U'%>MB;.8QM=LG<J8.>3
M'09/)6*79;I,TL0R<\->M)8,L,$;2O`RD/(L:DQHSD(\9K&5@QEJR*-6QDH1
M;-.K7N<UYYHD<U8VLR)&$>5@BL.WA7<A2W:"S"C?1NSFM[NZ+(NX)\K*-J@_
M63J^'JW(JJB%8Q+73J-*HW+&K.'!(>3L)%GUWL:"*JY"6>SV!%-0[,T<5CJ?
MK='=IT[]V^R>1=#F/%TC,8_1.X+'9JQ>RFKGBE^U(!C-E)66;1I92A/7"9`(
MC&WB.B#.'"2Z;1=RT2)(N-)F[INZ("C9P@Y3X)RJV<-7*)Q.0BI#$.W=.#>2
M*D`W)?<=P""#A<Q5BH]T]@W-HOM#`U-@Y+&Y/:V*QM/&X^?%R"2%/AZ\7JI.
M`28[KNQFMJY]1YY'DD`9RHYN[ABSB9K)3[EJW*6:O6Y[ER"]$8Y1)+*P^1R?
MWT/RD12*%3M':HX75QJ40Y$/R$!_AP'Y>H^0_+T'4W(!ZCQJ'(?4/XAI\@L5
M!5VC8@$/&0KJ?!Y4D$#[>Q]]:;Y@#VLR$JR]R\=P#J5/'((\JQ'D'WUKIN$V
MX5O<&QK(2$VXJ%@JKY\+.T,(5M-/'$%(H)D7@EVQI&$6.BC(!]JLE%))5-H8
M9)!NW34EU5TM4/[F;"@'_MXD^./7^B%B(?ASQE/SP/@>.?D/S\*="/(#P(#X
M'Z<?V?QU:NG;5FB=R\<HM&Y`_6++'2(4H"($#@RRK='N,8Q2E]ZND3D1#O\`
M(`,/[LZ"])-ZYNQN'<NRJ>0R]N%/B\B<EFL5`PKJ!ZMU\7D:<9ED!4"657/$
M;!>T!N7SB>JF_P#;&+IXK#;BGK8ZF%@KU6I8FVWSL2`LE^A9=23W$A"H/@=O
M@<)GCTSH7_CXDOE_[H6'U\CYRH'CCCCT]0UZ*F]*&4R%<*W0<=Y-MU]OMNED
M8:I4NMX:CG4U9910Z1!:,BFR@LU1;(&63&5DY#W</#M15=S+ANQ1<*%<3[1>
MEAO'WD.(^7JE"7Q-B5TJW.YS/F*-F*Q6W$8MRHM(TBN.FC2WWXY&Z"HLE82,
M3I[QZY:M'MYB$O?.B/'MB738VZ;#8%P.-XY>WY5L,:DRN^<+@#%Y>I]`HMUU
MH>']PF=E4*8#Y$KMK5X@WN%E4FYYES.NVB3[5/.LD/X4.G-*WBL+LK';GWJ\
M4T45+&;HW7;PN)E>)ECER.1.<=)+->0+*V-$3M*.V-U1).]9VV!;Z\[OFBNY
M'<DV%P*-&[SS8?;C37H.8W<5NW$)(GJ1%@LO*HIY*OW#C7B^EKL?R'M)V@;4
M\8;G+30LY;A=M^,[+BVEY:;T]-E:\=8FM4K#2C##<=:GLS97$C'U"$@*S1_M
M6$_1^*DJ[4*Q&(Q)BPRTY.JDMBF(@F0YA.8I>#'$W<)Q`1#O$>"AR8/O"!2@
M4HB)2AV@&J222:8G,4XCW^H"83#S]\0^\(=QN`-V`)C&$"%(4#`4A0U=$X[0
MX]/E^7(\:H1-/+:EDF93##W,M6HID]"K79C(M>!)7E>*")VD,,9E9OWLKR-)
M)(SZLW#'Z4:HK"0$!IINV-3//VJIED]-44R$#@E41>.`J*H4";1HT:\]>VC1
MHT:-&C1HT:-&C1HT:-&C1HT:-&C0(`(<"`"'T'R&C1HT:AP'CP'CR'@/`_4-
M'`?0/X:CHTA`/N`?IY`]O'C_`$'\AHU#M+]`^OH'J/J.@2E'U`!_,`^7I_#4
M=&E``)('!/DD>"2.`"?OP`/?[#[:"`?<<\^#S]OM_H-2B0@CR)2B/U$H"/CT
M\B'RU'M+SSVEYXXYX#GCZ<^O'X:CHT<#DGCR1VD_4J/8$_4#D^/;SI.U?L/?
MN]A_%]_U_/WU+VE\_=+Y]?`>>?7GQH["<\]A>1\"/:'(A].>.=3:-8]B#@!5
M`!Y`[1X/W'CP?S]]*?/OY_74.TO^2'CT\!XT``!Z``?D'&HZ-+P.>>!S]_KI
M``/8`?IXU`2E$0$2@(ASP(@'(<^O`_+GYZ.`$!`0`0'GD.`X'GUY#T\_/4=&
ME^WY>WY?I]M'`!)``)]SQY/Z_?V&H`4I>1*4`$>!'@`#D0```1X]>```#GY`
M`>FHZ-&CW]_.EU#@/H'GU\>NC@/H'\`U'1H]_?SHX'//'G[_`%U`0`>.0`>!
MY#D`'@?J'/H.H"4H^I2C^8`/^D-3:-'TX^A]Q]#_`):/M^7M^7Z?;4.TOG[I
M?/KX#S^>H=I?\DO\`_/Z?7SJ;1H(!]QS^ND``'```YYX'@<CV/'W_/5N[127
M;.$%DDET%D3HKH+)IJHKH*%$BJ"R2A3IJ(JIF,FHF<IBF(8Q1*(#QI,;.W2$
MZ?NX)RZF[/MZKU!ML@"XO+;A1])XFE7+ER=L=R\DV=*6B:G8GS@&:)59*RU:
M7?$*986Z[8RZQU%/E0`4S`/D./\`7JBF`!V\!QSQSQXYYX]>/]@^6MMA-Q[D
MVQ>3(;9SF7P%M`O%S#96YC;`*D]HXK%4<#GGER>?X2O`&O@R.'Q68K-6RV-H
MY*LWAHK<"2\<D$]I93V\\\DC@\_7R=-H+Y[-/A:1,[6Q1NHS/2#+%7,T8WZJ
MTG*42R543.5J!@C"XRGG[9LH*1E$GUA4=.$DSH@[0[RF2P@'LQ]Z[@`V_NL&
M+W%%3C9S(E[B\AW!YW:BF(B`B!1536(0P@8R9A*&G9@F,)^.1X^@"(!Z<^@<
M?/4#E`/(<\B/U$?K\A'C4N0?B@Z]TXC!%U`R$ZA>TM>JX.[+-R02]B>W@[$T
MTC'EFDE>5V?YBQ/D,.;HSTRGX9MHXT!RO/#6P?H1X6PH'MP>.`1IMWC_`-FQ
MV_1!VR^4MR.<[XJD!`<QU0BL?XV@GG:GPH11%Y$7^QIHG6X521;VM+W!>$2G
MX#NTIWMZZ6VQ3;.\:3F,]N=0<W)@9,[:_9'6?99O2#AN83HO8F>R`_GQJ[D#
M<&']%TH=`0(3]442\BH8!0`H"'/(\\_>-]`^7/`>H\\>NH$`"A]T`+ZAX``^
M8A]/Y^NF7N+K+U3WDKT-P[ZW%:@E(=J,5R*KC&^4*RO3H5Z$#J1V\+)#(`1R
MO8W).[Q/3K9."D67%;5PE>52H6P]<SV(2I!1J\DYE:)OF/+*RMX'!^@G0`W:
M83^1[QXY4!3P`=H&#C@I!,'(B0@%*4!X`/41K"4H^I2CP("'(`/D/0?S#Y#\
MM2IAP`_F/^K4^F`/;R%_11P/!\<`\_K[^_G3P`X'')/YGCD_KQX\>!^@&C@`
0]``-&C1I=+HT:-&C1K__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
